probucol has been researched along with Kidney Diseases in 15 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the preventive effect of probucol combined with hydration on contrast-induced nephropathy (CIN) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI)." | 9.27 | The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study. ( Cong, H; Fu, N; Liang, M; Lin, W; Lu, C; Tian, F; Yang, S; Zhang, J; Zhang, P, 2018) |
| "To investigate the preventive effect of probucol combined with hydration on contrast-induced nephropathy (CIN) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI)." | 5.27 | The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study. ( Cong, H; Fu, N; Liang, M; Lin, W; Lu, C; Tian, F; Yang, S; Zhang, J; Zhang, P, 2018) |
| " The authors treated a 36-year-old woman with LPG and exhibiting a nephrotic syndrome using an intensive lipid-lowering therapy consisting of fenofibrate (300 mg), niceritrol (750 mg), ethyl-icosapentate (1,800 mg), and probucol (500 mg)." | 3.72 | Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. ( Hotta, O; Ieiri, N; Taguma, Y, 2003) |
| "Treatment with probucol resulted in the improvement of both hyperlipoproteinemia and proteinuria with the disappearance of the lipoprotein thrombi in the glomerular capillary without any change in the mesangial IgA deposition." | 2.39 | A case of lipoprotein glomerulopathy successfully treated with probucol. ( Amenomori, M; Haneda, M; Hidaka, H; Kikkawa, R; Maeda, S; Morikawa, J; Nishigaki, I; Shigeta, Y, 1994) |
| "Probucol has a more pronounced health benefit than high-dose CoQ(10) supplementation and uniquely restores CoQ(9) content in mutant kidney." | 1.37 | Probucol ameliorates renal and metabolic sequelae of primary CoQ deficiency in Pdss2 mutant mice. ( Chen, JY; Clarke, CF; Falk, MJ; Gasser, DL; Horyn, O; King, R; Maltzman, JS; Marbois, B; Nakamaru-Ogiso, E; Nissim, I; Okwuego, E; Ostrovsky, J; Peng, M; Polyak, E; Xie, LX; Zhang, Z, 2011) |
| "Cephaloridine (CER) has been used to elucidate the mechanisms of cephalosporin antibiotic-induced nephrotoxicity." | 1.30 | Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity. ( Endou, H; Hosoyamada, M; Kanai, Y; Sekine, T; Takeda, M; Tojo, A, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Pranata, R | 1 |
| Yonas, E | 1 |
| Vania, R | 1 |
| Lukito, AA | 1 |
| Fu, N | 1 |
| Yang, S | 1 |
| Zhang, J | 1 |
| Zhang, P | 1 |
| Liang, M | 1 |
| Cong, H | 1 |
| Lin, W | 1 |
| Tian, F | 1 |
| Lu, C | 1 |
| Zhou, G | 1 |
| Wang, Y | 1 |
| He, P | 2 |
| Li, D | 1 |
| Wang, N | 1 |
| Wei, RB | 1 |
| Li, QP | 1 |
| Yang, X | 1 |
| Li, P | 1 |
| Huang, MJ | 1 |
| Wang, R | 1 |
| Cai, GY | 1 |
| Chen, XM | 1 |
| Kawamura, H | 1 |
| Takemoto, M | 1 |
| Maezawa, Y | 1 |
| Ishikawa, T | 1 |
| Ishibashi, R | 1 |
| Sakamoto, K | 1 |
| Shoji, M | 1 |
| Hattori, A | 1 |
| Yamaga, M | 1 |
| Ide, S | 1 |
| Ide, K | 1 |
| Hayashi, A | 1 |
| Tokuyama, H | 1 |
| Kobayashi, K | 1 |
| Yokote, K | 1 |
| Ames, PR | 1 |
| Matsunaga, A | 1 |
| Furuyama, M | 1 |
| Hashimoto, T | 1 |
| Toyoda, K | 1 |
| Ogino, D | 1 |
| Hayasaka, K | 1 |
| Yasuda, G | 1 |
| Ando, D | 1 |
| Hirawa, N | 1 |
| Umemura, S | 1 |
| Falk, MJ | 1 |
| Polyak, E | 1 |
| Zhang, Z | 1 |
| Peng, M | 1 |
| King, R | 1 |
| Maltzman, JS | 1 |
| Okwuego, E | 1 |
| Horyn, O | 1 |
| Nakamaru-Ogiso, E | 1 |
| Ostrovsky, J | 1 |
| Xie, LX | 1 |
| Chen, JY | 1 |
| Marbois, B | 1 |
| Nissim, I | 1 |
| Clarke, CF | 1 |
| Gasser, DL | 1 |
| Ieiri, N | 1 |
| Hotta, O | 1 |
| Taguma, Y | 1 |
| Yoshida, M | 1 |
| Kimura, H | 1 |
| Kyuki, K | 1 |
| Ito, M | 1 |
| Amenomori, M | 1 |
| Haneda, M | 1 |
| Morikawa, J | 1 |
| Nishigaki, I | 1 |
| Maeda, S | 1 |
| Hidaka, H | 1 |
| Kikkawa, R | 1 |
| Shigeta, Y | 1 |
| Abdel-Naim, AB | 1 |
| Abdel-Wahab, MH | 1 |
| Attia, FF | 1 |
| Takeda, M | 1 |
| Tojo, A | 1 |
| Sekine, T | 1 |
| Hosoyamada, M | 1 |
| Kanai, Y | 1 |
| Endou, H | 1 |
| Hirano, T | 1 |
| Yoshino, G | 1 |
3 reviews available for probucol and Kidney Diseases
| Article | Year |
|---|---|
The role of probucol preventing contrast-induced nephropathy in patients undergoing invasive coronary procedures - Systematic review and meta-analysis of randomized controlled trials.
Topics: Antioxidants; Confidence Intervals; Contrast Media; Coronary Angiography; Creatinine; Fluid Therapy; | 2021 |
A case of lipoprotein glomerulopathy successfully treated with probucol.
Topics: Female; Glomerulonephritis, IGA; Humans; Hyperlipoproteinemia Type III; Kidney Diseases; Lipids; Mid | 1994 |
[Treatments for dyslipidemia associated with kidney disease].
Topics: Anion Exchange Resins; Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibit | 2001 |
2 trials available for probucol and Kidney Diseases
| Article | Year |
|---|---|
The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.
Topics: Aged; Antioxidants; Combined Modality Therapy; Contrast Media; Coronary Disease; Creatinine; Cystati | 2018 |
Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Hu | 2010 |
10 other studies available for probucol and Kidney Diseases
| Article | Year |
|---|---|
Probucol inhibited Nox2 expression and attenuated podocyte injury in type 2 diabetic nephropathy of db/db mice.
Topics: Albuminuria; Animals; Antioxidants; Collagen Type IV; Diabetes Mellitus, Type 2; Disease Models, Ani | 2013 |
Renal Protective Effect of Probucol in Rats with Contrast-Induced Nephropathy and its Underlying Mechanism.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acetylcysteine; Animals; Antioxidants; Contrast Media; Creatinine; Deox | 2015 |
Combination of cilostazol and probucol protected podocytes from lipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanisms.
Topics: Albuminuria; Animals; Anti-Inflammatory Agents; Antioxidants; Cells, Cultured; Chemokine CCL2; Cilos | 2017 |
Antiphospholipid antibodies in systemic sclerosis: a double oxidative hit?
Topics: Antibodies, Antiphospholipid; Antioxidants; Humans; Hypolipidemic Agents; Kidney Diseases; Oxidative | 2009 |
Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Apoli | 2009 |
Probucol ameliorates renal and metabolic sequelae of primary CoQ deficiency in Pdss2 mutant mice.
Topics: Albuminuria; Alkyl and Aryl Transferases; Animals; Anticholesteremic Agents; Antioxidants; Energy Me | 2011 |
Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins E; Drug Combinations; Eicosapentaenoic Acid; Female | 2003 |
Combined effect of probucol and insulin on renal damage in diabetic rats fed a high cholesterol diet.
Topics: Albuminuria; Animals; Anticholesteremic Agents; Antioxidants; Blood Glucose; Cholesterol; Cholestero | 2006 |
Protective effects of vitamin e and probucol against gentamicin-induced nephrotoxicity in rats.
Topics: Acetylglucosaminidase; Animals; Anticholesteremic Agents; Creatinine; Drug Synergism; gamma-Glutamyl | 1999 |
Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity.
Topics: Animals; Anion Transport Proteins; Anticholesteremic Agents; Antigens, Polyomavirus Transforming; Bi | 1999 |